The study examined hematological, renal, and hepatic toxicities, as well as the onset or worsening of xerostomia, demonstrating that [225Ac]Ac-PSMA therapy was generally well tolerated, with few severe adverse effects, primarily hematologic. The gene discussed is FOLH1; the disease is xerostomia.